ARQ 197: Phase I data

In an open-label, dose-escalation, U.K. Phase I trial in 14 patients, 300 mg of ARQ 197 twice-daily was the maximum tolerated dose (MTD) and the recommended Phase II dose. In 11 evaluable patients, se...